Hypertension and nephrology

[First experiences with percutaneous renal denervation in management of resistant hypertension]

SCHULCZ Domonkos1, NAGY Ferenc Tamás2, THURY Attila2, BAJCSI Dóra1, FEJES Imola1, LETOHA Annamária1, CONSTANTINOU Kypros1, UNGI Imre2, ÁBRAHÁM György1, LÉGRÁDY Péter1

APRIL 08, 2017

Hypertension and nephrology - 2017;21(02)

[Percutaneous transluminal radiofrequency renal denervation is a promising new therapeutic method for the treatment of primary resistant hypertension. The intervention decreases the systemic sympathetic over activation and thus arterial blood pressure. In the 1st Department of Medicine of the University of Szeged, 9 resistant hypertensive patients (2 male, 7 female; mean age: 55.0±4.0 years) had all the conditions were required for renal denervation at the time of interventions were performed. We measured the blood pressure together with the heart rate of the patients on the day preceding the intervention, right after the intervention, at discharge from hospital, then at months 6, 9 and 15. The mean blood pressure was 178/107±7/5 mmHg before the intervention. After denervation mean blood pressure decreased right after the intervention, at discharge from hospital, as well as at months 6, 9 and 15, respectively -15/-17 mmHg; -36/-16 mmHg; -19/-9 mmHg; -27/-21 mmHg and -15/- 16 mmHg. Besides decreasing of blood pressure, the antihypertensive drug therapy also decreased, however, it was not the primary aim of the intervention. No denervation- related intra- or perivascular complications were detected. The findings of our study proved the efficacy and safety of renal denervation in the treatment of primary resistant hypertension, of course with an appropriate patient selection. Our study was not relevant to determine whether this method is accompanied with a significant decrease of cardiovascular morbidity and mortality. Answers may come only based on randomized sham controlled studies with great case numbers.]

AFFILIATIONS

  1. Szegedi Tudományegyetem, Általános Orvostudományi Kar, I. Sz. Belgyógyászati Klinika, Nephrologia-Hypertonia Centrum, Szeged
  2. Szegedi Tudományegyetem, Általános Orvostudományi Kar, II. Sz. Belgyógyászati Klinika és Kardiológiai Központ, Invazív Kardiológiai Részleg, Szeged

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Thought about the SPRINT Study Comments to Publication “Critical Evaluation and Practical Value of the SPRINT Study Results” [Kiss I, Kékes E. Hypertonia Nephrologia 2017;21(1):34-6.]]

BAJNOK László

Hypertension and nephrology

[Preferred Drug Groups, Active Substances and Combinations in European and Hungarian Recommendations]

BARABÁS Noémi

Hypertension and nephrology

[Letter to our Readers]

KÉKES Ede, KISS István

Hypertension and nephrology

[The History of Hypertension – Paul Dudley White (1886-1973)]

KÉKES Ede, NAGY Judit

Hypertension and nephrology

[Efficacy of a fixed-dose association of amlodipine and lisinopril in grade II and III hypertensive patients]

JOÃO Maldonado, TEIMO Pereira, MARGARIDA Carvalho

[We conducted an observational study, with ambulatory blood pressure monitoring (ABPM), to evaluate the efficacy of a fixed-dose combination of Amlodipine (5 mg) and Lisinopril (20 mg) in grade II and III hypertensive patients, over an 8 week intervention period. Thirty non-medicated hypertensive patients were enrolled, 36% female, with a mean age of 52.44±11.54 years, a body mass index of 28.73±4.54 kg/m2, and brachial office systolic (SBP) and diastolic (DBP) blood pressure of 174.43±15.06 mmHg and 102.83±10.67 mmHg, respectively. All patients performed a 24 hours ABPM at baseline and after a treatment period of 8 weeks with the fixed-dose association. Brachial office blood pressure and routine blood and urine samples were also obtained in both moments. A significant reduction in blood pressure was observed after the treatment with the fixed-dose association. The proportion of patients with controlled ambulatory blood pressure after the treatment was 69%, considering the normalization of the systolic and diastolic ambulatory pressures over the daytime, nighttime and 24 hours. Considering the brachial office blood pressures, the proportion of controlled hypertensive patients reached 79%. A significant improvement was also seen in microalbuminuria (reduction of 37.40 mg/24h; IC: 2.82-71.97; p=0.035) and fasting glycaemia (reduction of 11.53 mg/dl; IC: 3.46-19.61; p=0.007). No side effects were reported during the 8 week treatment period. The treatment of grade II and III hypertensive patients with a fixed-dose association of Amlodipine (5 mg) and Lisinopril (20 mg) during 8 weeks is effective controlling blood pressure. Furthermore, evidences indicate that the efficacy of the association is achieved quickly, safely and with good tolerability.]

All articles in the issue

Related contents

Hypertension and nephrology

[Association between cyclothymic affective temperament and hypertension]

NEMCSIK János, BATTA Dóra, KŐRÖSI Beáta, RIHMER Zoltán

[Affective temperaments (cyclothymic, hypertymic, depressive, anxious, irritable) are stable parts of personality and after adolescent only their minor changes are detectable. Their connections with psychopathology is well-described; depressive temperament plays role in major depression, cyclothymic temperament in bipolar II disorder, while hyperthymic temperament in bipolar I disorder. Moreover, scientific data of the last decade suggest, that affective temperaments are also associated with somatic diseases. Cyclothymic temperament is supposed to have the closest connection with hypertension. The prevalence of hypertension is higher parallel with the presence of dominant cyclothymic affective temperament and in this condition the frequency of cardiovascular complications in hypertensive patients was also described to be higher. In chronic hypertensive patients cyclothymic temperament score is positively associated with systolic blood pressure and in women with the earlier development of hypertension. The background of these associations is probably based on the more prevalent presence of common risk factors (smoking, obesity, alcoholism) with more pronounced cyclothymic temperament. The scientific importance of the research of the associations of personality traits including affective temperaments with somatic disorders can help in the identification of higher risk patient subgroups.]

Hypertension and nephrology

[The new European ESH/ESC guidelines - Part II. Therapy]

FARSANG Csaba

[The most important features of the new European joint hypertension guidelines of the European Society of Hypertension (ESH) and European Society of Cardiology became available as lectures at the ESH meeting in Barcelona, in 2018 June, while the publication came out in the Journal of Hypertension and also in the European Heart Journal in August, 2018. Based on the published new guidelines I summarise its most important therapeutic suggestions.]

Lege Artis Medicinae

[UNIQUE BENEFITS OF INDAPAMIDE TREATMENT]

NAGY Viktor

[The benefit of blood pressure lowering to high risk cardiovascular patients is proven. Thiazides are first line agents of blood pressure lowering treatment. Indapamide has both thiazide-like and vasodilator effects. Randomized controlled trials have shown that slow release indapamide of 1.5 mg efficiently lowers blood pressure, as well as the risk of various cardiovascular events (left ventricular hypertrophy, secondary stroke, progression of nephropathy etc.). Due to the low dose, the drug is well tolerated. Slow release indapamide is therefore an ideal choice as monotherapy for the beginning of blood pressure lowering treatment, and it is also a base drug of combination treatments.]

Hypertension and nephrology

[Hypertension and left ventricular hypertrophy]

MATOLTSY András

[Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the left ventricle. In addition to the absolute increase in mass, the geometric pattern of LVH also may be important. LVH can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness. This increase in mass predominantly results from a chronic increase in afterload of LV caused by the hypertension, although there is also a genetic component. A significant increase in the number and/or size of sarcomeres is the main pathologic mechanism, but hypertension may also result in interstitial fibrosis. The estimation of mass is commonly derived from measurements obtained by echocardiography. LVH is associated with increased incidence of systolic and/or diastolic dysfunction, heart failure, myocardial infarction, ventricular arrhythmias, sudden cardiac death, aortic root dilatation, and a cerebrovascular event. The cardiovascular risk is directly related to the degree of mass. The regression of LVH is associated with a reduction in cardiovascular risk and improved cardiac function. Regression of LVH is associated with weight loss, dietary sodium restriction, and use of ACE inhibitors, ARBs, some calcium channel blockers, and some sympatholytic agents.]

Clinical Neuroscience

[The effect of angiotensin receptor blockers in cerebrovascular disorders and dementia: Bonus in addition to the antihypertensive effect]

KOVÁCS Tibor

[Hypertension and dementia are frequent disorders or rather syndromes. Their incidence is growing with advancing age and hypertension is increasing the risk of cognitive impairment too, while treating hypertension (i.e. the use of antihypertensive medications) is decreasing it. In addition, hypertension is the most important risk factor for stroke. The renin-angiotensin system (RAS) has a special role in the development of hypertension and also involved in the pathogenesis of the most frequent dementia form, namely Alzheimer’s disease. The effect of angiotensin convertase inhibitors and angiotensin receptor blockers (ARB) is based on the inhibition of the RAS, but the ARBs do not inhibit angiotensin formation, just blocking its harmful effects on the AT1 receptor, while allowing the activation of AT2 receptors with pleiotropic effects. Preclinical, epidemiological and clinical therapeutic studies suggest this additional effect of ARBs and these are summarized in this review.]